Clinical Study
HPV Prevalence and Prognostic Value in a Prospective Cohort of 255 Patients with Locally Advanced HNSCC: A Single-Centre Experience
Table 1
Patient characteristics according to HPV status.
| | Patient characteristic | Number of patients | | HPV+ | HPV− | P | Total |
| | Number of patients | 175 | 80 | | | | Age (years) | | | | | | Median | 55.42 | 59.56 | t-test | 57.00 | | Range | 25.25–75.03 | 39.64–78.72 | 25.25–78.72 | | T () | | | | | | T1 | 36 (20.57%) | 7 (8.75%) | Fisher | 43 (16.86%) | | T2 | 39 (22.29%) | 17 (21.25%) | 56 (21.96%) | | T3 | 48 (27.43%) | 26 (32.50%) | 74 (29.02%) | | T4 | 51 (29.14%) | 25 (31.25%) | 76 (29.80%) | | TX | 0 | 1 (1.25%) | 1 (0.39%) | | Recurrence | 1 (0.57%) | 4 (5.00%) | 5 (1.96%) | | N ()* | | | | | | N0 | 15 (8.62%) | 11 (13.75%) | Fisher | 26 (10.24%) | | N1 | 25 (14.37%) | 10 (12.50%) | 35 (13.78%) | | N2 | 0 | 1 (1.25%) | 1 (0.39%) | | N2a | 27 (15.52%) | 10 (12.50%) | 37 (14.57%) | | N2b | 42 (24.14%) | 16 (20.00%) | 58 (22.83%) | | N2c | 36 (20.69%) | 22 (27.50%) | 58 (22.83%) | | N3 | 29 (16.67%) | 10 (12.50%) | 39 (15.35%) | | TNM stage () | | | | | | I | 0 | 0 | Fisher | 0 (0%) | | II | 0 | 2 (2.5%) | 2 (0.78%) | | III | 24 (13.71%) | 11 (13.75%) | 35 (13. 73%) | | IVa | 117 (68.86%) | 49 (61.25%) | 166 (65.10%) | | IVb | 30 (17.14%) | 14 (17.50%) | 44 (17.25%) | | Recurrence | 4 (2.29%) | 4 (5.00%) | 8 (3.14%) | | KPS ()* | | | | | | 60 | 1 (0.67%) | 0 | Fisher | 1 (0.47%) | | 70 | 3 (2.00%) | 1 (1.61%) | 4 (1.89%) | | 80 | 30 (20.00%) | 11 (17.74%) | 41 (19.34%) | | 90 | 99 (66.00%) | 49 (79.03%) | 148 (69.81%) | | 100 | 17 (11.33%) | 1 (1.61%) | 18 (8.49%) | | Chemotherapy ()* | | | | | | Daily Carboplatin or Cisplatin | 17 (9.71%) | 10 (12.66%) | Fisher | 27 (10.63%) | | Daily Carboplatin + 5FU | 113 (64.57%) | 33 (41.77%) | 146 (57.48%) | | Cisplatin q 1 week or q 3 weeks | 45 (25.71%) | 36 (45.57%) | 81 (31.89%) | | Radiotherapy ()* | | | | | | Conventional | 143 (82.18%) | 77 (96.25%) | Fisher | 220 (86.28%) | | IMRT | 31 (17.82%) | 3 (3.75%) | 34 (13.33%) | | Primary () | | | | | | Oropharynx | 137 (78.29%) | 32 (40.00%) | Fisher | 169 (66.27%) | | Larynx | 14 (8.00%) | 18 (22.50%) | 32 (12.54%) | | Oral cavity | 9 (5.14%) | 16 (20.00%) | 25 (9.80%) | | Hypopharynx | 6 (3.43%) | 9 (11.25%) | 15 (5.88%) | | Nasopharynx | 6 (3.43%) | 2 (2.50%) | 8 (3.14%) | | Paranasal sinuses | 2 (1.14%) | 1 (1.25%) | 3 (1.18%) | | Nose | 1 (0.57%) | 1 (1.25%) | 2 (0.78%) | | Unknown | 0 | 1 (1.25%) | 1 (0.39%) |
|
|
Indicates missing data.
|
